Judit Henczkó

Mrs. Judit Henczkó

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2024 in Viruses
Verified
Journal Article
Open access
PDF file
NDNóra Deézsi-Magyar
Nóra Deézsi-Magyar
Béla DénesBéla Dénes
Béla Dénes
BNBereniké Novák
Bereniké Novák
GZGyula Zsidei
Gyula Zsidei
DDDániel Déri
Dániel Déri
KZKis Zoltan
Kis Zoltan
(1) Background: Crimean–Congo hemorrhagic fever (CCHF) is an emerging tick-borne disease endemic in Africa, Asia, the Middle East, and the Balkan and Mediterranean regions of Europe. Although no human CCHF cases have been reported, based on vector presence, serological evidence among small vertebrates, and the general human population, Hungary lies within high evidence consensus for potential CCHF introduction and future human infection. Thus, the aim of our pilot serosurvey was to assess CCHF seropositivity among cattle and sheep as indicator animals for virus circulation in the country. (2) Methods: In total, 1905 serum samples taken from free-range cattle and sheep in 2017 were tested for the presence of anti-CCHF virus IgG antibodies using commercial ELISA and commercial and in-house immunofluorescent assays. (3) Results: We found a total of eleven reactive samples (0.58%) from five administrative districts of Hungary comprising 8 cattle and 3 sheep. The most affected regions were the south–central and northwestern parts of the country. (4) Conclusions: Based on these results, more extended surveillance is advised, especially in the affected areas, and there should be greater awareness among clinicians and other high-risk populations of the emerging threat of CCHF in Hungary and Central Europe.

20 July 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
ATAlina Tscherne
Alina Tscherne
EMEnrico Mantel
Enrico Mantel
TBTalar Boskani
Talar Boskani
SBSylwia Budniak
Sylwia Budniak
MEMandy Carolina Elschner
Mandy Carolina Elschner
SZSabine Zange
Sabine Zange
Brucellosis, mainly caused by Brucella (B.) melitensis, is associated with a risk of chronification and relapses. Antimicrobial susceptibility testing (AST) standards for B. melitensis are not available, and the agent is not yet listed in the EUCAST breakpoint tables. CLSI recommendations for B. melitensis exist, but they do not fulfill the requirements of the ISO 20776 standard regarding the culture medium and the incubation conditions. Under the third EU Health Programme, laboratories specializing in the diagnostics of highly pathogenic bacteria in their respective countries formed a working group within a Joint Action aiming to develop a suitable method for the AST of B. melitensis. Under the supervision of EUCAST representatives, this working group adapted the CLSI M45 document to the ISO 20776 standard after testing and validation. These adaptations included the comparison of various culture media, culture conditions and AST methods. A Standard Operation Procedure was derived and an interlaboratory validation was performed in order to evaluate the method. The results showed pros and cons for both of the two methods but also indicate that it is not necessary to abandon Mueller–Hinton without additives for the AST of B. melitensis.

31 October 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
JHJudit Henczkó
Judit Henczkó
ÁTÁkos Tóth
Ákos Tóth
MKMárta Knausz
Márta Knausz
BGBéla Gartner
Béla Gartner
ÁRÁkos Reményi
Ákos Reményi
KZKis Zoltan
Kis Zoltan
Background: Burkholderia pseudomallei, the causative agent of melioidosis, is a neglected tropical pathogen that has been increasingly encountered in Europe through travel-related infections. Clinical manifestations range from localized abscesses to life-threatening sepsis, posing diagnostic challenges in non-endemic regions. Methods: We report two travel-associated melioidosis cases confirmed in Hungary between 2008 and 2024. Whole-genome sequencing (WGS), multilocus sequence typing (MLST), and core-genome MLST (cgMLST) were performed for molecular characterization. In parallel, a systematic review of travel-related melioidosis cases reported in Europe (1980–2025) was conducted according to PRISMA 2020 guidelines. Data were retrieved from PubMed, Scopus, Google Scholar, and the PubMLST database. Results: In silico MLST identified two distinct sequence types (STs): a novel ST1643, and ST1051, previously reported in Asia and Australia. Both isolates clustered within the Asian clade, confirming an imported origin. Virulence profiling revealed major determinants, including the Yersinia-like fimbriae (YLF) cluster, fhaB3, and ITS type C. The ST1643 isolate carried the bimABm variant and multiple resistance genes (blaOXA-57, blaPenI, and amrAB efflux system), while ST1051 harbored blaOXA-59. The literature review identified 82 studies encompassing 195 European cases, most originating from Southeast Asia, with pneumonia, followed by septic form and abscess as the predominant presentation. We found only eight neuromelioidosis cases in Europe. Conclusions: This study represents the first report of neuromelioidosis in Hungary, and the first global description of ST1643. Combined genomic and epidemiological data highlight the need for improved clinical awareness, genomic surveillance, and diagnostic preparedness in non-endemic regions, as global travel and climate change expand the distribution of melioidosis.

23 April 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
JHJudit Henczkó
Judit Henczkó
ZKZsuzsa Kienle
Zsuzsa Kienle
JKJános Kádár
János Kádár
EKEnikő Kádár-Hürkecz
Enikő Kádár-Hürkecz
KTKatalin Tárnoki-Boross
Katalin Tárnoki-Boross
KZKis Zoltan
Kis Zoltan
Background: Brucellosis is a globally distributed zoonotic disease characterized by highly variable clinical manifestations that may mimic systemic autoimmune and inflammatory disorders. In Europe, where the incidence of brucellosis is relatively low, limited clinical awareness may contribute to delayed diagnosis and inappropriate management. In addition to zoonotic transmission, Brucella species are a well-recognized cause of laboratory-acquired infections (LAIs) among microbiology laboratory personnel. Methods: We report a case of laboratory-acquired Brucella abortus infection in a young woman presenting with undulant fever, arthralgia, systemic inflammation, elevated ferritin levels, and antinuclear antibody (ANA) positivity. Microbiological confirmation was achieved through serological testing (ELISA), repeat blood cultures, species-specific quantitative PCR, and whole-genome sequencing (WGS) followed by core genome multilocus sequence typing (cgMLST). Results: Initial laboratory evaluation revealed elevated C-reactive protein, mildly increased ferritin levels (146 ng/mL), abnormal liver enzyme levels, and rising ANA titers (from 1:160 to 1:320), raising suspicion of a systemic autoimmune disorder and prompting consideration of corticosteroid therapy. Although the initial blood culture was negative, subsequent molecular diagnostics and repeat cultures confirmed B. abortus infection. Epidemiological investigation suggested a possible occupational exposure in a diagnostic microbiology laboratory, consistent with a laboratory-acquired infection. Genomic analysis classified the isolate as sequence type 1 (ST1) and demonstrated zero allelic differences compared with the ST1 reference strain. Targeted antimicrobial therapy resulted in complete clinical recovery, supporting an infection-triggered immune response rather than primary autoimmunity. Conclusions: Acute brucellosis should be considered in the differential diagnosis of febrile syndromes accompanied by autoimmune-like laboratory abnormalities, even in low-incidence regions. This case highlights the diagnostic challenges posed by laboratory-acquired brucellosis and underscores the importance of early microbiological investigation and strict biosafety awareness in laboratory settings.